Accelerating MASH trials: from biopsy to biomarkers The Lancet Gastroenterology & Hepatology +++ +... (Jan 2026 Volume 11Number 1p1-86)

Linerixibat in patients with primary biliary cholangitis and cholestatic pruritus (GLISTEN): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial https://www.thelancet.com/journals/langas/article/PIIS2468-1253(25)00192-X/abstract?dgcid=raven_jbs_etoc_feature_langas Vedolizumab in early and late Crohn's disease (LOVE-CD): a phase 4 open-label cohort study https://www.thelancet.com/journals/langas/article/PIIS2468-1253(25)00233-X/abstract?dgcid=raven_jbs_etoc_feature_langas Accelerating MASH trials: from biopsy to biomarkers The Lancet Gastroenterology & Hepatology https://www.thelancet.com/journals/langas/article/PIIS2468-1253(25)00352-8/fulltext?dgcid=raven_jbs_etoc_email Jan 2026 Volume 11Number 1p1-86 https://www.thelancet.com/journals/langas/issue/vol11no1/PIIS2468-1253(25)X0012-1